The Concentration of Cyclosporine Metabolites Is Significantly Lower in Kidney Transplant Recipients With Diabetes Mellitus

被引:25
作者
Akhlaghi, Fatemeh [1 ]
Dostalek, Miroslav [1 ]
Falck, Pal [2 ]
Mendonza, Anisha E. [1 ]
Amundsen, Rune [2 ]
Gohh, Reginald Y. [3 ]
Asberg, Anders [2 ]
机构
[1] Univ Rhode Isl, Clin Pharmacokinet Res Lab, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA
[2] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway
[3] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Organ Transplantat, Providence, RI 02903 USA
关键词
biotransformation; cyclosporine; cytochrome P450 3A4; diabetes mellitus; pharmacokinetics; ketoconazole; TANDEM MASS-SPECTROMETRY; P-GLYCOPROTEIN; KETOCONAZOLE; PHARMACOKINETICS; ELUCIDATION; DISPOSITION; PATHWAYS; CYP3A5; PLASMA; BLOOD;
D O I
10.1097/FTD.0b013e318241ac71
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
100118 [医学信息学]; 100208 [临床检验诊断学];
摘要
Background: Diabetes mellitus is prevalent among kidney transplant recipients. The activity of drug metabolizing enzymes or transporters may be altered by diabetes leading to changes in the concentration of parent drug or metabolites. This study was aimed to characterize the effect of diabetes on the concentration of cyclosporine (CsA) and metabolites. Methods: Concentration-time profiles of CsA and metabolites (AM1, AM9, AM4N, AM1c, AM19, and AM1c9) were characterized over a 12-hour dosing interval in 10 nondiabetic and 7 diabetic stable kidney transplant recipients. All patients were male, had nonfunctional CYP3A5*3 genotype, and were on combination therapy with ketoconazole. Results: The average daily dose (+/- SD) of CsA was 65 +/- 21 and 68 +/- 35 mg in nondiabetic and diabetic subjects, respectively (P = 0.550). Cyclosporine metabolites that involved amino acid 1 (AM1, AM19, AM1c) exhibited significantly lower dose-normalized values of area under the concentration-time curve in patients with diabetes. Moreover, during the postabsorption phase (>= 3 hours after dose), metabolite-parent concentration ratios for all metabolites, except AM4N, was significantly lower in diabetic patients. The pharmacokinetic parameters of ketoconazole were similar between the 2 groups thus excluding inconsistent ketoconazole exposure as a source of altered CsA metabolism. Conclusions: This study indicates that diabetes mellitus significantly affects the concentration of CsA metabolites. Because CsA is eliminated as metabolites via the biliary route, the decrease in the blood concentration of CsA metabolites during postabsorption phase would probably reflect lower hepatic cytochrome P450 3A4 enzyme activity. However, other mechanisms including altered expression of transporters may also play a role. Results of cyclosporine therapeutic drug monitoring in diabetic patients must be interpreted with caution when nonspecific assays are used.
引用
收藏
页码:38 / 45
页数:8
相关论文
共 31 条
[1]
Distribution of cyclosporin in organ transplant recipients [J].
Akhlaghi, F ;
Trull, AK .
CLINICAL PHARMACOKINETICS, 2002, 41 (09) :615-637
[2]
INVESTIGATIONS ON THE METABOLIC PATHWAYS OF CYCLOSPORINE .1. EXCRETION OF CYCLOSPORINE AND ITS METABOLITES IN HUMAN BILE ISOLATION OF 12 NEW CYCLOSPORINE METABOLITES [J].
CHRISTIANS, U ;
STROHMEYER, S ;
KOWNATZKI, R ;
SCHIEBEL, HM ;
BLECK, J ;
GREIPEL, J ;
KOHLHAW, K ;
SCHOTTMANN, R ;
SEWING, KF .
XENOBIOTICA, 1991, 21 (09) :1185-1198
[3]
INVESTIGATIONS ON THE METABOLIC PATHWAYS OF CYCLOSPORINE .2. ELUCIDATION OF THE METABOLIC PATHWAYS INVITRO BY HUMAN LIVER-MICROSOMES [J].
CHRISTIANS, U ;
STROHMEYER, S ;
KOWNATZKI, R ;
SCHIEBEL, HM ;
BLECK, J ;
KOHLHAW, K ;
SCHOTTMANN, R ;
SEWING, KF .
XENOBIOTICA, 1991, 21 (09) :1199-1210
[4]
ALTERNATIVE CYCLOSPORINE METABOLIC PATHWAYS AND TOXICITY [J].
CHRISTIANS, U ;
SEWING, KF .
CLINICAL BIOCHEMISTRY, 1995, 28 (06) :547-559
[5]
In vitro metabolism of cyclosporine A by human kidney CYP3A5 [J].
Dai, Y ;
Iwanaga, K ;
Lin, YS ;
Hebert, MF ;
Davis, CL ;
Huang, WL ;
Kharasch, ED ;
Thummel, KE .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (09) :1889-1902
[6]
Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus [J].
Dantas Moises, Elaine Christine ;
Duarte, Luciana de Barros ;
Cavalli, Ricardo de Carvalho ;
Marques, Maria Paula ;
Lanchote, Vera Lucia ;
Duarte, Geraldo ;
da Cunha, Sergio Pereira .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (12) :1189-1196
[7]
In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine-Treated as Compared With Tacrolimus-Treated Renal Allograft Recipients [J].
de Jonge, H. ;
de Loor, H. ;
Verbeke, K. ;
Vanrenterghem, Y. ;
Kuypers, D. R. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (03) :414-422
[8]
Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus [J].
Dostalek, Miroslav ;
Court, Michael H. ;
Yan, Bingfang ;
Akhlaghi, Fatemeh .
BRITISH JOURNAL OF PHARMACOLOGY, 2011, 163 (05) :937-947
[9]
Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1′-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry [J].
Dostalek, Miroslav ;
Macwan, Joyce S. ;
Chitnis, Shripad D. ;
Ionita, Ileana A. ;
Akhlaghi, Fatemeh .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2010, 878 (19) :1629-1633
[10]
CYCLOSPORINE CLINICAL PHARMACOKINETICS [J].
FAHR, A .
CLINICAL PHARMACOKINETICS, 1993, 24 (06) :472-495